A thrombus forms when the body’s clotting system activates inside a blood vessel at the wrong time or wrong place, building a solid mass of platelets, fibrin, and trapped blood cells that can partially or fully block blood flow. The process relies on the same machinery that stops bleeding after a cut, but when it misfires, it can trigger heart attacks, strokes, pulmonary embolism, and other life-threatening events. What makes thrombus formation so clinically important is that the causes are varied, the types of clots differ depending on where they form, and the risks compound in ways that are not always obvious.
Why Clots Form Where They Shouldn’t
The framework most clinicians still use to think about unwanted clotting dates back over a century: three broad categories of problems, any combination of which can tip the balance from normal blood flow to dangerous clot formation. These are changes in blood composition, damage or dysfunction of the vessel wall, and abnormal blood flow patterns.
Blood composition is the most studied piece. Higher-than-normal levels of clotting proteins like prothrombin and fibrinogen raise the risk of a clot, while deficiencies in other factors cause bleeding disorders instead.1PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited The vessel wall contributes surface molecules that recruit platelets and white blood cells to injury sites. It also provides tissue factor, a protein that essentially announces a breach in the vessel and kickstarts the coagulation cascade. Blood flow matters because the speed and turbulence of blood influence how quickly platelets and clotting proteins reach an injury, how strongly platelets stick, and how efficiently fibrin networks assemble.1PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited
No single abnormality in any one of these three areas reliably predicts who will develop a dangerous clot. That is part of what makes thrombosis difficult to prevent: it is nearly always the result of multiple factors interacting at once. Someone with slightly elevated clotting proteins and slightly sluggish blood flow in one leg might be fine for decades, then develop a clot after a long-haul flight or surgery when the balance tips just enough.
The Step-by-Step Buildup of a Clot
When a blood vessel is injured, a protein called von Willebrand factor acts as the first responder. It latches onto the exposed tissue beneath the vessel lining and then grabs passing platelets through receptors on their surface, pulling them into contact with the wound.2PubMed Central. Of von Willebrand factor and platelets Under normal conditions, von Willebrand factor keeps a portion of itself folded up to prevent accidental platelet binding. When blood flow applies enough mechanical force, that folded shield peels away, exposing the binding site and allowing platelets to stick.3Nature Communications. Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module
Once platelets begin accumulating, they activate and release chemical signals that recruit even more platelets, forming a soft initial plug. Simultaneously, the coagulation cascade converts the circulating protein fibrinogen into fibrin strands. Thrombin, the key enzyme in this cascade, clips small pieces off fibrinogen molecules, which then link together into a three-dimensional mesh that reinforces and stabilizes the plug.4PubMed Central. Fibrinogen and Fibrin in Hemostasis and Thrombosis Under healthy circumstances, the body dissolves this temporary patch once the vessel has healed. When that cleanup system falters or the clot-forming signals keep firing, you get a thrombus that can grow large enough to block the vessel or break loose and travel elsewhere.
Arterial Versus Venous Clots
Not all thrombi look the same, and the old shorthand that arterial clots are “white” while venous clots are “red” is a rough guide at best. Both kinds contain fibrin, platelets, red blood cells, and white blood cells. The difference is in proportions, driven largely by the flow environment where they form.5PubMed. Venous and Arterial Thromboses: Two Sides of the Same Coin?
Arterial clots form in fast-flowing, high-pressure vessels. They tend to be rich in fibrin and platelets. One analysis of coronary artery thrombi found they were composed of roughly 43% fibrin and 31% platelets by volume. Venous clots, forming in slower-flow, lower-pressure veins, trap far more red blood cells, which accounted for about 63% of the volume in venous thrombi from the same study, with platelet content dropping to under 1%.6Scientific Reports. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli This compositional split matters for treatment. Drugs that target platelet activation work well against arterial clots. Anticoagulants that disrupt the fibrin-forming cascade are central to managing venous clots.
Stroke clots illustrate how blurry the arterial-venous distinction can be in practice. Thrombi retrieved from the brain arteries of stroke patients contain both platelet-rich and red-blood-cell-rich regions, and clot composition varies from patient to patient in ways that influence how easy the clot is to remove.7PubMed Central. Thrombus Structural Composition in Cardiovascular Disease
What Happens When a Plaque Ruptures
Most heart attacks begin not with a clot that forms spontaneously but with a crack in a fatty deposit (plaque) lining a coronary artery. When the thin cap over a plaque breaks open, the fatty core beneath it is exposed to flowing blood. That core is loaded with tissue factor, which fires up the coagulation cascade in a massive way.8PubMed. The role of plaque rupture and thrombosis in coronary artery disease The clot that forms on a ruptured plaque contains not just aggregated platelets but also large amounts of fibrin, because the tissue factor signal is so strong.9PubMed Central. Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques
The plaques most prone to rupture have a specific structure: a relatively large necrotic (dead-tissue) core capped by a thin fibrous layer typically thinner than 65 micrometers, heavily infiltrated by immune cells called macrophages.10PubMed Central. Pathology of coronary atherosclerosis and thrombosis A plaque can sit in an artery for years without causing symptoms, then rupture with little warning when inflammation weakens the cap. This is why some people who feel perfectly healthy suffer sudden cardiac events.
Genetic and Acquired Risk Factors
Some people carry inherited mutations that tilt their clotting system toward overactivity. Five well-established genetic defects raise venous thrombosis risk. Deficiencies in protein C, protein S, and antithrombin account for about 15% of families with inherited clotting tendencies. The more common culprits are the factor V Leiden mutation and the prothrombin 20210A variant, which together appear in roughly 63% of those families.11Clinical Chemistry. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk Factor V Leiden is the single most common inherited form of thrombophilia, with the prothrombin variant as the second most common, occurring in roughly 2-3% of European and American populations.12PubMed Central. Hereditary thrombophilia
Carrying one of these mutations does not mean a clot is inevitable. Many carriers go through life without a single thrombotic event. The danger rises when genetic susceptibility collides with acquired risk factors: surgery, immobility, cancer, hormone therapy, or pregnancy. Pregnant women face up to five times the normal risk of deep vein thrombosis, and pulmonary embolism from such clots is the leading cause of maternal death in the developed world.13PubMed Central. Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management
Autoimmune conditions can also push clotting into overdrive. In antiphospholipid syndrome, the immune system produces antibodies that activate endothelial cells, platelets, and neutrophils, while simultaneously reducing the body’s ability to dissolve clots. The result is clots that are denser, less permeable, and harder for the body’s natural cleanup system to break down.14PubMed Central. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System The antibodies target a phospholipid-binding protein in the blood, and their high affinity for cell membranes appears to be a critical step in driving the disease.15PubMed. Molecular pathogenesis of the antiphospholipid syndrome
Cerebral Venous Thrombosis and Unusual Locations
Most conversations about stroke focus on arterial blockages, but clots can also form in the large veins that drain blood from the brain. Cerebral venous sinus thrombosis is uncommon, and it can mimic an arterial stroke so closely that initial misdiagnosis is a real concern.16PubMed Central. Cerebral Venous Sinus Thrombosis Presenting as an Acute Stroke Syndrome What distinguishes it mechanistically is that venous blockage raises pressure in the veins and capillaries of the brain, reducing blood perfusion and increasing intracranial pressure. Headache is a common early symptom. Compared with arterial strokes, venous strombosis in the brain is also more prone to causing bleeding, because the pressure buildup can rupture small capillaries.17Frontiers in Neurology. Venous stroke–a stroke subtype that should not be ignored
Animal models of this condition show the hallmarks seen in human patients: extensive fibrin-rich clots in small veins, brain swelling, and both ischemic and hemorrhagic damage.18PubMed. A Novel Mouse Model for Cerebral Venous Sinus Thrombosis Young women, people on oral contraceptives, and those with infections or autoimmune conditions face higher risk for this type of thrombosis. Awareness has grown after some COVID-19 vaccines were linked to rare cases, though the absolute numbers remained very small.
Disseminated Intravascular Coagulation
At the extreme end of clotting gone wrong sits a condition where clotting and bleeding happen simultaneously throughout the body. In disseminated intravascular coagulation, a massive trigger like severe sepsis, major trauma, or certain cancers sets off runaway thrombin production. Tiny clots form in small blood vessels across multiple organs while, paradoxically, the clotting factors and platelets get used up so rapidly that the patient also bleeds uncontrollably.19PubMed Central. Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy
The widespread small-vessel clotting can starve organs of oxygen. In the lungs, for example, fibrin deposits are a characteristic feature, and the resulting oxygen deprivation can trigger acute respiratory distress syndrome. The inflammatory cytokines driving this process also worsen blood vessel leakiness and tissue damage, creating a destructive cycle.20PubMed. Microvascular coagulopathy and disseminated intravascular coagulation This condition is never a standalone disease; it is always secondary to something else. Treating it means treating the underlying cause while trying to support the failing clotting system.
Neutrophil Traps and Shear Gradients
Research in the past decade has identified mechanisms of clot formation that the classical framework did not account for. One is the role of neutrophil extracellular traps, or NETs. Neutrophils, a type of white blood cell, can release web-like structures made of their own DNA and enzymes as a defense against invading pathogens. These webs catch and kill bacteria effectively, but the same structures can also activate the coagulation pathway and serve as a scaffold for pathological clot formation.21PubMed Central. Impact of Neutrophil Extracellular Traps on Thrombosis Formation: New Findings and Future Perspective This helps explain why infections and inflammatory conditions carry such a high thrombosis risk: the immune system’s own weapons double as pro-clotting agents.
Blood flow dynamics have also turned out to be more complex than a simple fast-versus-slow distinction. Shear rate gradients, meaning areas where blood velocity changes rapidly over a short distance, can supercharge platelet adhesion even on surfaces that would normally be weak triggers for clotting. Lab experiments show that when these gradients are steep enough, platelet aggregates grow massive and can occlude flow channels entirely.22Haematologica. Shear rate gradients promote a bi-phasic thrombus formation on weak adhesive proteins, such as fibrinogen in a VWF-dependent manner This is clinically relevant in arteries narrowed by plaque, where blood squeezes through a tight gap and accelerates, creating exactly the kind of velocity change that promotes aggressive clotting. At these high shear rates, clot formation depends heavily on von Willebrand factor and platelets, with the fluid dynamics influencing every stage from initial binding to rapid clot growth.23PubMed. Thrombus Formation at High Shear Rates
How Clots Are Detected
When a deep vein thrombosis is suspected, clinicians typically combine a clinical probability assessment with a blood test called D-dimer. D-dimer measures a fragment released when fibrin is broken down, so elevated levels suggest active clotting somewhere in the body. The test is extremely sensitive: in one study, every patient with a normal D-dimer level turned out to be free of DVT.24PubMed Central. Appropriate Use of Venous Imaging and Analysis of the D-Dimer/Clinical Probability Testing Paradigm in the Diagnosis and Location of Deep Venous Thrombosis The catch is that D-dimer has poor specificity. Inflammation, infection, recent surgery, pregnancy, and even older age can all push D-dimer above normal without any clot being present. A normal result is very good at ruling DVT out; an elevated result just means further imaging is needed.
Ultrasound is the standard follow-up. A typical approach checks the veins at two points; if those are clear but the D-dimer is elevated, a repeat ultrasound about a week later catches the small number of cases that were too early to see on the first scan. In a randomized trial comparing this strategy to a single whole-leg scan, about 5.5% of patients with abnormal D-dimer results and initially normal ultrasound had abnormal findings on repeat imaging.25JAMA. Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis: A Randomized Controlled Trial For arterial clots, imaging depends on the location: CT angiography for pulmonary embolism, catheter-based angiography for coronary arteries during a heart attack, and CT or MR venography for cerebral venous thrombosis.
Treatment Strategies and How They Match the Clot
Because arterial and venous clots differ in composition, their treatments target different parts of the clotting machinery. Antiplatelet drugs like aspirin and clopidogrel inhibit platelet activation and aggregation, which is the dominant process in forming arterial thrombi. Anticoagulants like heparin and warfarin, as well as newer direct oral anticoagulants, work on the coagulation cascade itself, suppressing thrombin generation and fibrin formation, making them the backbone of venous thromboembolism treatment.26PubMed Central. Antiplatelet, anticoagulant or both? A tool for pharmacists Some situations call for both: a patient with a coronary stent, for instance, often takes an antiplatelet drug and an anticoagulant simultaneously for a period, which underscores the overlap between arterial and venous clotting biology.
When a clot is already blocking a critical vessel, the goal shifts from prevention to removal. Tissue plasminogen activator (tPA) is a clot-dissolving drug given intravenously for certain strokes and pulmonary embolisms. For large-vessel strokes, combining intravenous tPA with mechanical thrombectomy, where a catheter physically retrieves the clot, produces better blood flow restoration and long-term functional outcomes than mechanical retrieval alone.27PubMed Central. Intravenous Tissue Plasminogen Activator in Combination With Mechanical Thrombectomy For deep vein thrombosis that is extensive or limb-threatening, catheter-directed techniques that combine clot-dissolving drugs with mechanical devices have achieved complete or partial clot removal in up to 84% of treated limbs.28PubMed. Pharmaco-mechanical thrombectomy for early thrombus removal
Clots Triggered by Medical Devices
Implanted devices that contact blood, from heart valves to vascular stents to dialysis catheters, face a fundamental biological problem. The body reads any foreign surface as an injury, so proteins and platelets stick to it, sometimes building a thrombus on the device itself.29PubMed Central. Unravelling Surface Modification Strategies for Preventing Medical Device-Induced Thrombosis Even modern metallic stents with improved coatings can provoke local inflammation when first implanted and accumulate unwanted protein deposits over time.30PubMed Central. Engineering Approaches to Prevent Blood Clotting from Medical Implants
This is why patients with mechanical heart valves take lifelong anticoagulants, and why people who receive coronary stents are prescribed dual antiplatelet therapy for months afterward. Researchers are working on surface coatings that mimic the blood vessel’s natural non-stick lining, but making an artificial surface that truly behaves like healthy endothelium over years of use remains one of the tougher problems in biomedical engineering. Until that is solved, device-related thrombosis will remain a consideration in the risk-benefit calculus of every implanted blood-contacting device.